featured
Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
J Thorac Oncol 2021 Nov 02;[EPub Ahead of Print], YL Wu, T John, C Grohe, M Majem, JW Goldman, SW Kim, T Kato, K Laktionov, HV Vu, Z Wang, S Lu, KY Lee, C Akewanlop, CJ Yu, F de Marinis, L Bonanno, M Domine, FA Shepherd, L Zeng, A Atasoy, RS Herbst, M TsuboiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.